Oculis Holding AG

Oculis Holding AG’s clinical wins—Privosegtor FDA nod and OCS‑01 Phase 3 readouts—boost its shares 6.2 %, but a negative P/E warns investors to watch financial sustainability while the biotech targets high‑impact retinal therapies.

A recent analyst valuation of Oculis Holding AG has set the company’s intrinsic value at €36 per share, significantly higher than its current market price, suggesting potential upside for long-term investors.